An HIV drug in development at Gilead Sciences as part of its programme to develop drug cocktails that could effect a functional cure has generated 'modest' results in its first clinical trial, according to the lead researcher on the project.
GT BIOPHARMA AND CYTOVANCE BIOLOGICS ANNOUNCE COLLABORATION AGREEMENT TRIKE(TM) THERAPEUTIC FOR TREATMENT OF CORONAVIRUS INFECTION
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure